

Global Third-party Pharmaceutical B2B Platform Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G574EFBA7FE9EN.html>

Date: June 2026

Pages: 209

Price: US\$ 4,480.00 (Single User License)

ID: G574EFBA7FE9EN

Abstracts

The global Third-party Pharmaceutical B2B Platform market size is expected to reach \$ 107492 million by 2032, rising at a market growth of 18.4% CAGR during the forecast period (2026-2032).

Third-party pharmaceutical B2B platform refers to an online trading platform operated by a third-party organization independent of pharmaceutical manufacturers and buyers, serving B2B participants in the pharmaceutical industry including pharmaceutical companies, wholesale distributors, retail pharmacies, and primary healthcare institutions. These platforms provide digital services for publishing pharmaceutical product information, order matching, online transactions, payment settlement, and supporting logistics information services for medicines, medical devices, health products, and other pharmaceutical-related products. The core characteristic of a third-party platform is its intermediary role?it does not directly participate in the purchase or sale of pharmaceuticals (i.e., does not take title to goods), but rather facilitates transactions between upstream and downstream participants and generates revenue through value-added services such as transaction commissions, membership fees, data services, and supply chain financing. This distinguishes third-party platforms from internal procurement systems built by pharmaceutical manufacturers or distributors. Major global platforms include OpenFDA Data Platform, EPharmConnect, Labviva in the United States, Pharmaoffer in Europe, and YSB, Yaojingcai, Jointown in China. Service coverage spans all pharmaceutical product categories including chemical drugs, traditional Chinese medicine, biologics, medical devices, health products, and herbal ingredients. Based on operating models, platforms can be categorized into pure matching platforms, hybrid platforms (matching + self-operated), and supply chain collaboration platforms.

Volume: platforms globally processed approximately USD 450-500 billion in GMV, with China accounting for about 40% (YSB GMV reached RMB 42.0 billion in 2024; Jointown, Yaojingcai, 1 Pharmacy aggregated over RMB 150 billion), North America ~30% (Cencora Marketplace, Labviva, Truepill), Europe and Middle East ~15%, India and Southeast Asia ~10%, Latin America and Africa ~5%. Price tiers by revenue model: transaction commissions dominate at 1.5-3% of GMV (2-3% typical in China, 1.5-2% in North America); annual membership fees USD 20,000-50,000 per enterprise (RMB 200,000-500,000 in China); data service reports RMB 50,000-200,000 (China) or USD 10,000-50,000 (North America); API access fees USD 10,000-100,000 annually; supply chain financing interest rates 8-15% APR (depending on credit rating). Gross margins by segment: pure matching platforms 60-80% (asset-light, no inventory risk, e.g., YSB, Yaozs); hybrid platforms (matching + self-operated) 25-40% (including inventory and fulfillment costs); API-first platforms 70-85% (technology-driven, low marginal cost); supply chain collaboration platforms 30-50% (including logistics and financing). Downstream primary applications: retail pharmacies (55-60% of platform volume, especially independent and small chain pharmacies), hospitals & clinics (15-20%, focused on compliant bulk procurement), pharmaceutical manufacturers (10-15%, purchasing APIs or selling finished products), wholesalers & distributors (5-10%, migrating B2B trading to platforms), primary care & community clinics (5-10%, in underserved areas). Growth applications: API-first procurement embedding (25-30% CAGR, large pharmacy chains and hospital groups integrating platforms via APIs) and cross-border pharmaceutical B2B trading (20-25% CAGR, platforms like Drugdu and Pharmaoffer facilitating international API and finished drug matching). Upstream: pharmaceutical and medical device manufacturers (global pharmaceutical market ~USD 1.6 trillion; global API market ~USD 220 billion). Midstream: third-party pharmaceutical B2B platforms including China market leaders (YSB, Jointown, Yaojingcai, 1 Pharmacy, Goldleta, Yaozs, Yaozhi, Global Pharmaceutical, Yajuduo), North America market leaders (Cencora Marketplace, Labviva, Truepill, TraceLink, GraphiteRx), European platforms (Pharmaoffer, AEP, Validaide, Zentiva), India and Southeast Asia platforms (PharmaHoppers, MedPro, PharmaSource D2R, Dawaai), Latin America and Middle East platforms (ConectNext, Yaydoo, MercadoLibre, Axmed), and cross-border platforms (Drugdu, Pharmint). Downstream: global pharmacies, hospitals, clinics, pharma companies, and wholesalers. Industry structure: highly regionalized, concentrated in China, technology-driven in North America, rapid rise in emerging markets. China market features a multi-strong landscape with YSB holding 15-20% market share; North America led by Cencora Marketplace (parent company annual revenue >USD 265 billion) with technology platforms like Labviva and Truepill dominating AI procurement and digital pharmacy; Europe characterized by cross-border API matching; India fragmented and undergoing consolidation; Latin America and Middle East seeing high

growth (30%+ CAGR). Uncertainties include varying pharmaceutical regulations (online prescription trading permissions, e-prescription interoperability), competition with distributors and manufacturers (some large pharma companies building in-house platforms), data security and privacy regulations, and cross-border e-commerce tariffs and compliance barriers. Conclusion: the third-party pharmaceutical B2B platform industry is in a growth-to-maturity transition phase (15-20% annual growth), driven by cost reduction and efficiency gains from pharmaceutical supply chain digitalization and unmet procurement needs of small-format buyers. Structural characteristic: China market mature and concentrated, North America technology-driven with room for penetration, emerging markets rapidly filling traditional distribution gaps, making it a core infrastructure of pharmaceutical distribution digital transformation.

This report studies the global Third-party Pharmaceutical B2B Platform demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Third-party Pharmaceutical B2B Platform, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Third-party Pharmaceutical B2B Platform that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Third-party Pharmaceutical B2B Platform total market, 2021-2032, (USD Million)

Global Third-party Pharmaceutical B2B Platform total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Third-party Pharmaceutical B2B Platform total market, key domestic companies, and share, (USD Million)

Global Third-party Pharmaceutical B2B Platform revenue by player, revenue and market share 2021-2026, (USD Million)

Global Third-party Pharmaceutical B2B Platform total market by Type, CAGR, 2021-2032, (USD Million)

Global Third-party Pharmaceutical B2B Platform total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Third-party Pharmaceutical B2B Platform market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include YSB (CN), Jointown (CN), Yaojingcai (CN), 1

Pharmacy (CN), Goldleta Pharmaceutical Trading Network (CN), Yaozs (CN), Yaozhi (CN), Global Pharmaceutical (CN), Yaomed (CN), Yajuduo (CN), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Third-party Pharmaceutical B2B Platform market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Third-party Pharmaceutical B2B Platform Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Third-party Pharmaceutical B2B Platform Market, Segmentation by Type:

Pure matching platform

Hybrid platform (matching + self-operated)

Supply chain collaboration platform

API-first platform

Global Third-party Pharmaceutical B2B Platform Market, Segmentation by Product Category:

Full-category pharmaceutical platform (approx. 55-60%)

API & bulk drug platform (approx. 15-20%)

Medical device & equipment platform (approx. 10-15%)

Chinese traditional medicine platform (approx. 8-12%)

Healthcare & wellness platform (approx. 5-8%)

Global Third-party Pharmaceutical B2B Platform Market, Segmentation by Module:

Online ordering & inventory management

Regulatory compliance & licensing

Cold chain validation

Sample & promotional product management

Price comparison & dynamic pricing

Others

Global Third-party Pharmaceutical B2B Platform Market, Segmentation by Core Revenue:

Commission-based

Subscription/membership

Service fee (SaaS/data)

Hybrid

Global Third-party Pharmaceutical B2B Platform Market, Segmentation by Application:

Retail pharmacies

Hospitals & clinics

Pharmaceutical manufacturers

Wholesalers & distributors

Primary care & community clinics

Others

Companies Profiled:

YSB (CN)

Jointown (CN)

Yaojingcai (CN)

1 Pharmacy (CN)

Goldleta Pharmaceutical Trading Network (CN)

Yaozs (CN)

Yaozhi (CN)

Global Pharmaceutical (CN)

Yaomed (CN)

Yajuduo (CN)

Drugdu (CN)

Labviva (US)

Cencora Marketplace (US)

Truepill (US)

TraceLink (US)

GraphiteRx (US)

MedWell Ai (US)

BoomRx (US)

Pharma Inquiry (US)

Pharmaoffer (NL)

AEP (DE)

Validaide (NL)

Sanicare (DE)

Zentiva (Zent2U) (CZ)

DawaDose (SA)

Dawaai (PK)

PharmaHopers (IN)

MedPro (IN)

PharmaSource D2R (IN)

Biddano (IN)

Pharmint (IN)

HealthCRAD Wholesale (IN)

TradeIndia (IN)

ChemDmart (IN)

ConectNext (MX)

Yaydoo (MX)

MercadoLibre (B2B Pharma) (AR)

Yeatrade (CO)

Axmed (CH)

Key Questions Answered

1. How big is the global Third-party Pharmaceutical B2B Platform market?
2. What is the demand of the global Third-party Pharmaceutical B2B Platform market?
3. What is the year over year growth of the global Third-party Pharmaceutical B2B Platform market?
4. What is the total value of the global Third-party Pharmaceutical B2B Platform market?
5. Who are the Major Players in the global Third-party Pharmaceutical B2B Platform market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Third-party Pharmaceutical B2B Platform Introduction
- 1.2 World Third-party Pharmaceutical B2B Platform Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Third-party Pharmaceutical B2B Platform Total Market by Region (by Headquarter Location)
 - 1.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.3 China Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.4 Europe Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.5 Japan Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
 - 1.3.8 India Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Third-party Pharmaceutical B2B Platform Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)
- 2.2 World Third-party Pharmaceutical B2B Platform Consumption Value by Region
 - 2.2.1 World Third-party Pharmaceutical B2B Platform Consumption Value by Region (2021-2026)
 - 2.2.2 World Third-party Pharmaceutical B2B Platform Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Third-party Pharmaceutical B2B Platform Consumption Value

(2021-2032)

2.4 China Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)

2.5 Europe Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)

2.6 Japan Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)

2.7 South Korea Third-party Pharmaceutical B2B Platform Consumption Value
(2021-2032)

2.8 ASEAN Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)

2.9 India Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032)

3 WORLD THIRD-PARTY PHARMACEUTICAL B2B PLATFORM COMPANIES COMPETITIVE ANALYSIS

3.1 World Third-party Pharmaceutical B2B Platform Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Third-party Pharmaceutical B2B Platform Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Third-party Pharmaceutical B2B Platform in
2025

3.2.3 Global Concentration Ratios (CR8) for Third-party Pharmaceutical B2B Platform in
2025

3.3 Third-party Pharmaceutical B2B Platform Company Evaluation Quadrant

3.4 Third-party Pharmaceutical B2B Platform Market: Overall Company Footprint
Analysis

3.4.1 Third-party Pharmaceutical B2B Platform Market: Region Footprint

3.4.2 Third-party Pharmaceutical B2B Platform Market: Company Product Type
Footprint

3.4.3 Third-party Pharmaceutical B2B Platform Market: Company Product Application
Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Third-party Pharmaceutical B2B Platform Revenue
Comparison (by Headquarter Location)

4.1.1 United States VS China: Third-party Pharmaceutical B2B Platform Revenue

Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: Third-party Pharmaceutical B2B Platform Revenue
Market Share Comparison (2021 & 2025 & 2032)

4.2 United States Based Companies VS China Based Companies: Third-party
Pharmaceutical B2B Platform Consumption Value Comparison

4.2.1 United States VS China: Third-party Pharmaceutical B2B Platform Consumption
Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Third-party Pharmaceutical B2B Platform Consumption
Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Third-party Pharmaceutical B2B Platform Companies and
Market Share, 2021-2026

4.3.1 United States Based Third-party Pharmaceutical B2B Platform Companies,
Headquarters (States, Country)

4.3.2 United States Based Companies Third-party Pharmaceutical B2B Platform
Revenue, (2021-2026)

4.4 China Based Companies Third-party Pharmaceutical B2B Platform Revenue and
Market Share, 2021-2026

4.4.1 China Based Third-party Pharmaceutical B2B Platform Companies, Company
Headquarters (Province, Country)

4.4.2 China Based Companies Third-party Pharmaceutical B2B Platform Revenue,
(2021-2026)

4.5 Rest of World Based Third-party Pharmaceutical B2B Platform Companies and
Market Share, 2021-2026

4.5.1 Rest of World Based Third-party Pharmaceutical B2B Platform Companies,
Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Third-party Pharmaceutical B2B Platform
Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Third-party Pharmaceutical B2B Platform Market Size Overview by Type:
2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Pure matching platform

5.2.2 Hybrid platform (matching + self-operated)

5.2.3 Supply chain collaboration platform

5.2.4 API-first platform

5.3 Market Segment by Type

5.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Type (2021-2026)

- 5.3.2 World Third-party Pharmaceutical B2B Platform Market Size by Type (2027-2032)
- 5.3.3 World Third-party Pharmaceutical B2B Platform Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY PRODUCT CATEGORY

- 6.1 World Third-party Pharmaceutical B2B Platform Market Size Overview by Product Category: 2021 VS 2025 VS 2032
- 6.2 Segment Introduction by Product Category
 - 6.2.1 Full-category pharmaceutical platform (approx. 55-60%)
 - 6.2.2 API & bulk drug platform (approx. 15-20%)
 - 6.2.3 Medical device & equipment platform (approx. 10-15%)
 - 6.2.4 Chinese traditional medicine platform (approx. 8-12%)
 - 6.2.5 Healthcare & wellness platform (approx. 5-8%)
- 6.3 Market Segment by Product Category
 - 6.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Product Category (2021-2026)
 - 6.3.2 World Third-party Pharmaceutical B2B Platform Market Size by Product Category (2027-2032)
 - 6.3.3 World Third-party Pharmaceutical B2B Platform Market Size Market Share by Product Category (2027-2032)

7 MARKET ANALYSIS BY MODULE

- 7.1 World Third-party Pharmaceutical B2B Platform Market Size Overview by Module: 2021 VS 2025 VS 2032
- 7.2 Segment Introduction by Module
 - 7.2.1 Online ordering & inventory management
 - 7.2.2 Regulatory compliance & licensing
 - 7.2.3 Cold chain validation
 - 7.2.4 Sample & promotional product management
 - 7.2.5 Price comparison & dynamic pricing
 - 7.2.6 Others
- 7.3 Market Segment by Module
 - 7.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Module (2021-2026)
 - 7.3.2 World Third-party Pharmaceutical B2B Platform Market Size by Module (2027-2032)
 - 7.3.3 World Third-party Pharmaceutical B2B Platform Market Size Market Share by

Module (2027-2032)

8 MARKET ANALYSIS BY CORE REVENUE

8.1 World Third-party Pharmaceutical B2B Platform Market Size Overview by Core Revenue: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Core Revenue

8.2.1 Commission-based

8.2.2 Subscription/membership

8.2.3 Service fee (SaaS/data)

8.2.4 Hybrid

8.3 Market Segment by Core Revenue

8.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Core Revenue (2021-2026)

8.3.2 World Third-party Pharmaceutical B2B Platform Market Size by Core Revenue (2027-2032)

8.3.3 World Third-party Pharmaceutical B2B Platform Market Size Market Share by Core Revenue (2027-2032)

9 MARKET ANALYSIS BY APPLICATION

9.1 World Third-party Pharmaceutical B2B Platform Market Size Overview by Application: 2021 VS 2025 VS 2032

9.2 Segment Introduction by Application

9.2.1 Retail pharmacies

9.2.2 Hospitals & clinics

9.2.3 Pharmaceutical manufacturers

9.2.4 Wholesalers & distributors

9.2.5 Primary care & community clinics

9.2.6 Others

9.3 Market Segment by Application

9.3.1 World Third-party Pharmaceutical B2B Platform Market Size by Application (2021-2026)

9.3.2 World Third-party Pharmaceutical B2B Platform Market Size by Application (2027-2032)

9.3.3 World Third-party Pharmaceutical B2B Platform Market Size Market Share by Application (2021-2032)

10 COMPANY PROFILES

10.1 YSB (CN)

10.1.1 YSB (CN) Details

10.1.2 YSB (CN) Major Business

10.1.3 YSB (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.1.4 YSB (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.1.5 YSB (CN) Recent Developments/Updates

10.1.6 YSB (CN) Competitive Strengths & Weaknesses

10.2 Jointown (CN)

10.2.1 Jointown (CN) Details

10.2.2 Jointown (CN) Major Business

10.2.3 Jointown (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.2.4 Jointown (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.2.5 Jointown (CN) Recent Developments/Updates

10.2.6 Jointown (CN) Competitive Strengths & Weaknesses

10.3 Yaojingcai (CN)

10.3.1 Yaojingcai (CN) Details

10.3.2 Yaojingcai (CN) Major Business

10.3.3 Yaojingcai (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.3.4 Yaojingcai (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.3.5 Yaojingcai (CN) Recent Developments/Updates

10.3.6 Yaojingcai (CN) Competitive Strengths & Weaknesses

10.4 1 Pharmacy (CN)

10.4.1 1 Pharmacy (CN) Details

10.4.2 1 Pharmacy (CN) Major Business

10.4.3 1 Pharmacy (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.4.4 1 Pharmacy (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.4.5 1 Pharmacy (CN) Recent Developments/Updates

10.4.6 1 Pharmacy (CN) Competitive Strengths & Weaknesses

10.5 Goldleta Pharmaceutical Trading Network (CN)

10.5.1 Goldleta Pharmaceutical Trading Network (CN) Details

10.5.2 Goldleta Pharmaceutical Trading Network (CN) Major Business

10.5.3 Goldleta Pharmaceutical Trading Network (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.5.4 Goldleta Pharmaceutical Trading Network (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.5.5 Goldleta Pharmaceutical Trading Network (CN) Recent Developments/Updates

10.5.6 Goldleta Pharmaceutical Trading Network (CN) Competitive Strengths & Weaknesses

10.6 Yaozs (CN)

10.6.1 Yaozs (CN) Details

10.6.2 Yaozs (CN) Major Business

10.6.3 Yaozs (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.6.4 Yaozs (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.6.5 Yaozs (CN) Recent Developments/Updates

10.6.6 Yaozs (CN) Competitive Strengths & Weaknesses

10.7 Yaozhi (CN)

10.7.1 Yaozhi (CN) Details

10.7.2 Yaozhi (CN) Major Business

10.7.3 Yaozhi (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.7.4 Yaozhi (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.7.5 Yaozhi (CN) Recent Developments/Updates

10.7.6 Yaozhi (CN) Competitive Strengths & Weaknesses

10.8 Global Pharmaceutical (CN)

10.8.1 Global Pharmaceutical (CN) Details

10.8.2 Global Pharmaceutical (CN) Major Business

10.8.3 Global Pharmaceutical (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.8.4 Global Pharmaceutical (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.8.5 Global Pharmaceutical (CN) Recent Developments/Updates

10.8.6 Global Pharmaceutical (CN) Competitive Strengths & Weaknesses

10.9 Yaomed (CN)

10.9.1 Yaomed (CN) Details

10.9.2 Yaomed (CN) Major Business

10.9.3 Yaomed (CN) Third-party Pharmaceutical B2B Platform Product and Services

10.9.4 Yaomed (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.9.5 Yaomed (CN) Recent Developments/Updates

10.9.6 Yaomed (CN) Competitive Strengths & Weaknesses

10.10 Yajuduo (CN)

- 10.10.1 Yajuduo (CN) Details
- 10.10.2 Yajuduo (CN) Major Business
- 10.10.3 Yajuduo (CN) Third-party Pharmaceutical B2B Platform Product and Services
- 10.10.4 Yajuduo (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.10.5 Yajuduo (CN) Recent Developments/Updates
- 10.10.6 Yajuduo (CN) Competitive Strengths & Weaknesses
- 10.11 Drugdu (CN)
 - 10.11.1 Drugdu (CN) Details
 - 10.11.2 Drugdu (CN) Major Business
 - 10.11.3 Drugdu (CN) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.11.4 Drugdu (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.11.5 Drugdu (CN) Recent Developments/Updates
 - 10.11.6 Drugdu (CN) Competitive Strengths & Weaknesses
- 10.12 Labviva (US)
 - 10.12.1 Labviva (US) Details
 - 10.12.2 Labviva (US) Major Business
 - 10.12.3 Labviva (US) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.12.4 Labviva (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.12.5 Labviva (US) Recent Developments/Updates
 - 10.12.6 Labviva (US) Competitive Strengths & Weaknesses
- 10.13 Cencora Marketplace (US)
 - 10.13.1 Cencora Marketplace (US) Details
 - 10.13.2 Cencora Marketplace (US) Major Business
 - 10.13.3 Cencora Marketplace (US) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.13.4 Cencora Marketplace (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.13.5 Cencora Marketplace (US) Recent Developments/Updates
 - 10.13.6 Cencora Marketplace (US) Competitive Strengths & Weaknesses
- 10.14 Truepill (US)
 - 10.14.1 Truepill (US) Details
 - 10.14.2 Truepill (US) Major Business
 - 10.14.3 Truepill (US) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.14.4 Truepill (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.14.5 Truepill (US) Recent Developments/Updates

10.14.6 Truepill (US) Competitive Strengths & Weaknesses

10.15 TraceLink (US)

10.15.1 TraceLink (US) Details

10.15.2 TraceLink (US) Major Business

10.15.3 TraceLink (US) Third-party Pharmaceutical B2B Platform Product and Services

10.15.4 TraceLink (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.15.5 TraceLink (US) Recent Developments/Updates

10.15.6 TraceLink (US) Competitive Strengths & Weaknesses

10.16 GraphiteRx (US)

10.16.1 GraphiteRx (US) Details

10.16.2 GraphiteRx (US) Major Business

10.16.3 GraphiteRx (US) Third-party Pharmaceutical B2B Platform Product and Services

10.16.4 GraphiteRx (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.16.5 GraphiteRx (US) Recent Developments/Updates

10.16.6 GraphiteRx (US) Competitive Strengths & Weaknesses

10.17 MedWell Ai (US)

10.17.1 MedWell Ai (US) Details

10.17.2 MedWell Ai (US) Major Business

10.17.3 MedWell Ai (US) Third-party Pharmaceutical B2B Platform Product and Services

10.17.4 MedWell Ai (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.17.5 MedWell Ai (US) Recent Developments/Updates

10.17.6 MedWell Ai (US) Competitive Strengths & Weaknesses

10.18 BoomRx (US)

10.18.1 BoomRx (US) Details

10.18.2 BoomRx (US) Major Business

10.18.3 BoomRx (US) Third-party Pharmaceutical B2B Platform Product and Services

10.18.4 BoomRx (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.18.5 BoomRx (US) Recent Developments/Updates

10.18.6 BoomRx (US) Competitive Strengths & Weaknesses

10.19 Pharma Inquiry (US)

10.19.1 Pharma Inquiry (US) Details

10.19.2 Pharma Inquiry (US) Major Business

10.19.3 Pharma Inquiry (US) Third-party Pharmaceutical B2B Platform Product and

Services

10.19.4 Pharma Inquiry (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.19.5 Pharma Inquiry (US) Recent Developments/Updates

10.19.6 Pharma Inquiry (US) Competitive Strengths & Weaknesses

10.20 Pharmaoffer (NL)

10.20.1 Pharmaoffer (NL) Details

10.20.2 Pharmaoffer (NL) Major Business

10.20.3 Pharmaoffer (NL) Third-party Pharmaceutical B2B Platform Product and Services

10.20.4 Pharmaoffer (NL) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.20.5 Pharmaoffer (NL) Recent Developments/Updates

10.20.6 Pharmaoffer (NL) Competitive Strengths & Weaknesses

10.21 AEP (DE)

10.21.1 AEP (DE) Details

10.21.2 AEP (DE) Major Business

10.21.3 AEP (DE) Third-party Pharmaceutical B2B Platform Product and Services

10.21.4 AEP (DE) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.21.5 AEP (DE) Recent Developments/Updates

10.21.6 AEP (DE) Competitive Strengths & Weaknesses

10.22 Validaide (NL)

10.22.1 Validaide (NL) Details

10.22.2 Validaide (NL) Major Business

10.22.3 Validaide (NL) Third-party Pharmaceutical B2B Platform Product and Services

10.22.4 Validaide (NL) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.22.5 Validaide (NL) Recent Developments/Updates

10.22.6 Validaide (NL) Competitive Strengths & Weaknesses

10.23 Sanicare (DE)

10.23.1 Sanicare (DE) Details

10.23.2 Sanicare (DE) Major Business

10.23.3 Sanicare (DE) Third-party Pharmaceutical B2B Platform Product and Services

10.23.4 Sanicare (DE) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.23.5 Sanicare (DE) Recent Developments/Updates

10.23.6 Sanicare (DE) Competitive Strengths & Weaknesses

10.24 Zentiva (Zent2U) (CZ)

- 10.24.1 Zentiva (Zent2U) (CZ) Details
- 10.24.2 Zentiva (Zent2U) (CZ) Major Business
- 10.24.3 Zentiva (Zent2U) (CZ) Third-party Pharmaceutical B2B Platform Product and Services
- 10.24.4 Zentiva (Zent2U) (CZ) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.24.5 Zentiva (Zent2U) (CZ) Recent Developments/Updates
- 10.24.6 Zentiva (Zent2U) (CZ) Competitive Strengths & Weaknesses
- 10.25 DawaDose (SA)
- 10.25.1 DawaDose (SA) Details
- 10.25.2 DawaDose (SA) Major Business
- 10.25.3 DawaDose (SA) Third-party Pharmaceutical B2B Platform Product and Services
- 10.25.4 DawaDose (SA) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.25.5 DawaDose (SA) Recent Developments/Updates
- 10.25.6 DawaDose (SA) Competitive Strengths & Weaknesses
- 10.26 Dawaai (PK)
- 10.26.1 Dawaai (PK) Details
- 10.26.2 Dawaai (PK) Major Business
- 10.26.3 Dawaai (PK) Third-party Pharmaceutical B2B Platform Product and Services
- 10.26.4 Dawaai (PK) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.26.5 Dawaai (PK) Recent Developments/Updates
- 10.26.6 Dawaai (PK) Competitive Strengths & Weaknesses
- 10.27 PharmaHoppers (IN)
- 10.27.1 PharmaHoppers (IN) Details
- 10.27.2 PharmaHoppers (IN) Major Business
- 10.27.3 PharmaHoppers (IN) Third-party Pharmaceutical B2B Platform Product and Services
- 10.27.4 PharmaHoppers (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.27.5 PharmaHoppers (IN) Recent Developments/Updates
- 10.27.6 PharmaHoppers (IN) Competitive Strengths & Weaknesses
- 10.28 MedPro (IN)
- 10.28.1 MedPro (IN) Details
- 10.28.2 MedPro (IN) Major Business
- 10.28.3 MedPro (IN) Third-party Pharmaceutical B2B Platform Product and Services
- 10.28.4 MedPro (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin

and Market Share (2021-2026)

10.28.5 MedPro (IN) Recent Developments/Updates

10.28.6 MedPro (IN) Competitive Strengths & Weaknesses

10.29 PharmaSource D2R (IN)

10.29.1 PharmaSource D2R (IN) Details

10.29.2 PharmaSource D2R (IN) Major Business

10.29.3 PharmaSource D2R (IN) Third-party Pharmaceutical B2B Platform Product and Services

10.29.4 PharmaSource D2R (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.29.5 PharmaSource D2R (IN) Recent Developments/Updates

10.29.6 PharmaSource D2R (IN) Competitive Strengths & Weaknesses

10.30 Biddano (IN)

10.30.1 Biddano (IN) Details

10.30.2 Biddano (IN) Major Business

10.30.3 Biddano (IN) Third-party Pharmaceutical B2B Platform Product and Services

10.30.4 Biddano (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.30.5 Biddano (IN) Recent Developments/Updates

10.30.6 Biddano (IN) Competitive Strengths & Weaknesses

10.31 Pharmint (IN)

10.31.1 Pharmint (IN) Details

10.31.2 Pharmint (IN) Major Business

10.31.3 Pharmint (IN) Third-party Pharmaceutical B2B Platform Product and Services

10.31.4 Pharmint (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.31.5 Pharmint (IN) Recent Developments/Updates

10.31.6 Pharmint (IN) Competitive Strengths & Weaknesses

10.32 HealthCRAD Wholesale (IN)

10.32.1 HealthCRAD Wholesale (IN) Details

10.32.2 HealthCRAD Wholesale (IN) Major Business

10.32.3 HealthCRAD Wholesale (IN) Third-party Pharmaceutical B2B Platform Product and Services

10.32.4 HealthCRAD Wholesale (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

10.32.5 HealthCRAD Wholesale (IN) Recent Developments/Updates

10.32.6 HealthCRAD Wholesale (IN) Competitive Strengths & Weaknesses

10.33 TradeIndia (IN)

10.33.1 TradeIndia (IN) Details

- 10.33.2 TradeIndia (IN) Major Business
- 10.33.3 TradeIndia (IN) Third-party Pharmaceutical B2B Platform Product and Services
- 10.33.4 TradeIndia (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.33.5 TradeIndia (IN) Recent Developments/Updates
- 10.33.6 TradeIndia (IN) Competitive Strengths & Weaknesses
- 10.34 ChemDmart (IN)
 - 10.34.1 ChemDmart (IN) Details
 - 10.34.2 ChemDmart (IN) Major Business
 - 10.34.3 ChemDmart (IN) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.34.4 ChemDmart (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.34.5 ChemDmart (IN) Recent Developments/Updates
 - 10.34.6 ChemDmart (IN) Competitive Strengths & Weaknesses
- 10.35 ConectNext (MX)
 - 10.35.1 ConectNext (MX) Details
 - 10.35.2 ConectNext (MX) Major Business
 - 10.35.3 ConectNext (MX) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.35.4 ConectNext (MX) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.35.5 ConectNext (MX) Recent Developments/Updates
 - 10.35.6 ConectNext (MX) Competitive Strengths & Weaknesses
- 10.36 Yaydoo (MX)
 - 10.36.1 Yaydoo (MX) Details
 - 10.36.2 Yaydoo (MX) Major Business
 - 10.36.3 Yaydoo (MX) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.36.4 Yaydoo (MX) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
 - 10.36.5 Yaydoo (MX) Recent Developments/Updates
 - 10.36.6 Yaydoo (MX) Competitive Strengths & Weaknesses
- 10.37 MercadoLibre (B2B Pharma) (AR)
 - 10.37.1 MercadoLibre (B2B Pharma) (AR) Details
 - 10.37.2 MercadoLibre (B2B Pharma) (AR) Major Business
 - 10.37.3 MercadoLibre (B2B Pharma) (AR) Third-party Pharmaceutical B2B Platform Product and Services
 - 10.37.4 MercadoLibre (B2B Pharma) (AR) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)

- 10.37.5 MercadoLibre (B2B Pharma) (AR) Recent Developments/Updates
- 10.37.6 MercadoLibre (B2B Pharma) (AR) Competitive Strengths & Weaknesses
- 10.38 Yeatrade (CO)
- 10.38.1 Yeatrade (CO) Details
- 10.38.2 Yeatrade (CO) Major Business
- 10.38.3 Yeatrade (CO) Third-party Pharmaceutical B2B Platform Product and Services
- 10.38.4 Yeatrade (CO) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.38.5 Yeatrade (CO) Recent Developments/Updates
- 10.38.6 Yeatrade (CO) Competitive Strengths & Weaknesses
- 10.39 Axmed (CH)
- 10.39.1 Axmed (CH) Details
- 10.39.2 Axmed (CH) Major Business
- 10.39.3 Axmed (CH) Third-party Pharmaceutical B2B Platform Product and Services
- 10.39.4 Axmed (CH) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026)
- 10.39.5 Axmed (CH) Recent Developments/Updates
- 10.39.6 Axmed (CH) Competitive Strengths & Weaknesses

11 INDUSTRY CHAIN ANALYSIS

- 11.1 Third-party Pharmaceutical B2B Platform Industry Chain
- 11.2 Third-party Pharmaceutical B2B Platform Upstream Analysis
- 11.3 Third-party Pharmaceutical B2B Platform Midstream Analysis
- 11.4 Third-party Pharmaceutical B2B Platform Downstream Analysis

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

- 13.1 Methodology
- 13.2 Research Process and Data Source
- 13.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Third-party Pharmaceutical B2B Platform Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Third-party Pharmaceutical B2B Platform Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Third-party Pharmaceutical B2B Platform Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Third-party Pharmaceutical B2B Platform Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Third-party Pharmaceutical B2B Platform Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Third-party Pharmaceutical B2B Platform Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Third-party Pharmaceutical B2B Platform Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Third-party Pharmaceutical B2B Platform Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Third-party Pharmaceutical B2B Platform Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Third-party Pharmaceutical B2B Platform Players in 2025

Table 12. World Third-party Pharmaceutical B2B Platform Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Third-party Pharmaceutical B2B Platform Company Evaluation Quadrant

Table 14. Head Office of Key Third-party Pharmaceutical B2B Platform Players

Table 15. Third-party Pharmaceutical B2B Platform Market: Company Product Type Footprint

Table 16. Third-party Pharmaceutical B2B Platform Market: Company Product Application Footprint

Table 17. Third-party Pharmaceutical B2B Platform Mergers & Acquisitions Activity

Table 18. United States VS China Third-party Pharmaceutical B2B Platform Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Third-party Pharmaceutical B2B Platform Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Third-party Pharmaceutical B2B Platform Companies, Headquarters (States, Country)

Table 21. United States Based Companies Third-party Pharmaceutical B2B Platform Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Third-party Pharmaceutical B2B Platform Revenue Market Share (2021-2026)

Table 23. China Based Third-party Pharmaceutical B2B Platform Companies, Headquarters (Province, Country)

Table 24. China Based Companies Third-party Pharmaceutical B2B Platform Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Third-party Pharmaceutical B2B Platform Revenue Market Share (2021-2026)

Table 26. Rest of World Based Third-party Pharmaceutical B2B Platform Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Third-party Pharmaceutical B2B Platform Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Third-party Pharmaceutical B2B Platform Revenue Market Share (2021-2026)

Table 29. World Third-party Pharmaceutical B2B Platform Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Third-party Pharmaceutical B2B Platform Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Third-party Pharmaceutical B2B Platform Market Size by Type (2027-2032) & (USD Million)

Table 32. World Third-party Pharmaceutical B2B Platform Market Size by Product Category, (USD Million), 2021 & 2025 & 2032

Table 33. World Third-party Pharmaceutical B2B Platform Market Size Value by Product Category (2021-2026) & (USD Million)

Table 34. World Third-party Pharmaceutical B2B Platform Market Size by Product Category (2027-2032) & (USD Million)

Table 35. World Third-party Pharmaceutical B2B Platform Market Size by Module, (USD Million), 2021 & 2025 & 2032

Table 36. World Third-party Pharmaceutical B2B Platform Market Size Value by Module (2021-2026) & (USD Million)

Table 37. World Third-party Pharmaceutical B2B Platform Market Size by Module (2027-2032) & (USD Million)

Table 38. World Third-party Pharmaceutical B2B Platform Market Size by Core Revenue, (USD Million), 2021 & 2025 & 2032

Table 39. World Third-party Pharmaceutical B2B Platform Market Size Value by Core

Revenue (2021-2026) & (USD Million)

Table 40. World Third-party Pharmaceutical B2B Platform Market Size by Core Revenue (2027-2032) & (USD Million)

Table 41. World Third-party Pharmaceutical B2B Platform Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 42. World Third-party Pharmaceutical B2B Platform Market Size by Application (2021-2026) & (USD Million)

Table 43. World Third-party Pharmaceutical B2B Platform Market Size by Application (2027-2032) & (USD Million)

Table 44. YSB (CN) Basic Information, Manufacturing Base and Competitors

Table 45. YSB (CN) Major Business

Table 46. YSB (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 47. YSB (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 48. YSB (CN) Recent Developments/Updates

Table 49. YSB (CN) Competitive Strengths & Weaknesses

Table 50. Jointown (CN) Basic Information, Manufacturing Base and Competitors

Table 51. Jointown (CN) Major Business

Table 52. Jointown (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 53. Jointown (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 54. Jointown (CN) Recent Developments/Updates

Table 55. Jointown (CN) Competitive Strengths & Weaknesses

Table 56. Yaojingcai (CN) Basic Information, Manufacturing Base and Competitors

Table 57. Yaojingcai (CN) Major Business

Table 58. Yaojingcai (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 59. Yaojingcai (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 60. Yaojingcai (CN) Recent Developments/Updates

Table 61. Yaojingcai (CN) Competitive Strengths & Weaknesses

Table 62. 1 Pharmacy (CN) Basic Information, Manufacturing Base and Competitors

Table 63. 1 Pharmacy (CN) Major Business

Table 64. 1 Pharmacy (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 65. 1 Pharmacy (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 66. 1 Pharmacy (CN) Recent Developments/Updates

Table 67. 1 Pharmacy (CN) Competitive Strengths & Weaknesses
Table 68. Goldleta Pharmaceutical Trading Network (CN) Basic Information, Manufacturing Base and Competitors
Table 69. Goldleta Pharmaceutical Trading Network (CN) Major Business
Table 70. Goldleta Pharmaceutical Trading Network (CN) Third-party Pharmaceutical B2B Platform Product and Services
Table 71. Goldleta Pharmaceutical Trading Network (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Goldleta Pharmaceutical Trading Network (CN) Recent Developments/Updates
Table 73. Goldleta Pharmaceutical Trading Network (CN) Competitive Strengths & Weaknesses
Table 74. Yaozs (CN) Basic Information, Manufacturing Base and Competitors
Table 75. Yaozs (CN) Major Business
Table 76. Yaozs (CN) Third-party Pharmaceutical B2B Platform Product and Services
Table 77. Yaozs (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Yaozs (CN) Recent Developments/Updates
Table 79. Yaozs (CN) Competitive Strengths & Weaknesses
Table 80. Yaozhi (CN) Basic Information, Manufacturing Base and Competitors
Table 81. Yaozhi (CN) Major Business
Table 82. Yaozhi (CN) Third-party Pharmaceutical B2B Platform Product and Services
Table 83. Yaozhi (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Yaozhi (CN) Recent Developments/Updates
Table 85. Yaozhi (CN) Competitive Strengths & Weaknesses
Table 86. Global Pharmaceutical (CN) Basic Information, Manufacturing Base and Competitors
Table 87. Global Pharmaceutical (CN) Major Business
Table 88. Global Pharmaceutical (CN) Third-party Pharmaceutical B2B Platform Product and Services
Table 89. Global Pharmaceutical (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. Global Pharmaceutical (CN) Recent Developments/Updates
Table 91. Global Pharmaceutical (CN) Competitive Strengths & Weaknesses
Table 92. Yaomed (CN) Basic Information, Manufacturing Base and Competitors
Table 93. Yaomed (CN) Major Business
Table 94. Yaomed (CN) Third-party Pharmaceutical B2B Platform Product and Services
Table 95. Yaomed (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross

Margin and Market Share (2021-2026) & (USD Million)

Table 96. Yaomed (CN) Recent Developments/Updates

Table 97. Yaomed (CN) Competitive Strengths & Weaknesses

Table 98. Yajuduo (CN) Basic Information, Manufacturing Base and Competitors

Table 99. Yajuduo (CN) Major Business

Table 100. Yajuduo (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 101. Yajuduo (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 102. Yajuduo (CN) Recent Developments/Updates

Table 103. Yajuduo (CN) Competitive Strengths & Weaknesses

Table 104. Drugdu (CN) Basic Information, Manufacturing Base and Competitors

Table 105. Drugdu (CN) Major Business

Table 106. Drugdu (CN) Third-party Pharmaceutical B2B Platform Product and Services

Table 107. Drugdu (CN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 108. Drugdu (CN) Recent Developments/Updates

Table 109. Drugdu (CN) Competitive Strengths & Weaknesses

Table 110. Labviva (US) Basic Information, Manufacturing Base and Competitors

Table 111. Labviva (US) Major Business

Table 112. Labviva (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 113. Labviva (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 114. Labviva (US) Recent Developments/Updates

Table 115. Labviva (US) Competitive Strengths & Weaknesses

Table 116. Cencora Marketplace (US) Basic Information, Manufacturing Base and Competitors

Table 117. Cencora Marketplace (US) Major Business

Table 118. Cencora Marketplace (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 119. Cencora Marketplace (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 120. Cencora Marketplace (US) Recent Developments/Updates

Table 121. Cencora Marketplace (US) Competitive Strengths & Weaknesses

Table 122. Truepill (US) Basic Information, Manufacturing Base and Competitors

Table 123. Truepill (US) Major Business

Table 124. Truepill (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 125. Truepill (US) Third-party Pharmaceutical B2B Platform Revenue, Gross

Margin and Market Share (2021-2026) & (USD Million)

Table 126. Truepill (US) Recent Developments/Updates

Table 127. Truepill (US) Competitive Strengths & Weaknesses

Table 128. TraceLink (US) Basic Information, Manufacturing Base and Competitors

Table 129. TraceLink (US) Major Business

Table 130. TraceLink (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 131. TraceLink (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 132. TraceLink (US) Recent Developments/Updates

Table 133. TraceLink (US) Competitive Strengths & Weaknesses

Table 134. GraphiteRx (US) Basic Information, Manufacturing Base and Competitors

Table 135. GraphiteRx (US) Major Business

Table 136. GraphiteRx (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 137. GraphiteRx (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 138. GraphiteRx (US) Recent Developments/Updates

Table 139. GraphiteRx (US) Competitive Strengths & Weaknesses

Table 140. MedWell Ai (US) Basic Information, Manufacturing Base and Competitors

Table 141. MedWell Ai (US) Major Business

Table 142. MedWell Ai (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 143. MedWell Ai (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 144. MedWell Ai (US) Recent Developments/Updates

Table 145. MedWell Ai (US) Competitive Strengths & Weaknesses

Table 146. BoomRx (US) Basic Information, Manufacturing Base and Competitors

Table 147. BoomRx (US) Major Business

Table 148. BoomRx (US) Third-party Pharmaceutical B2B Platform Product and Services

Table 149. BoomRx (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 150. BoomRx (US) Recent Developments/Updates

Table 151. BoomRx (US) Competitive Strengths & Weaknesses

Table 152. Pharma Inquiry (US) Basic Information, Manufacturing Base and Competitors

Table 153. Pharma Inquiry (US) Major Business

Table 154. Pharma Inquiry (US) Third-party Pharmaceutical B2B Platform Product and

Services

Table 155. Pharma Inquiry (US) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 156. Pharma Inquiry (US) Recent Developments/Updates

Table 157. Pharma Inquiry (US) Competitive Strengths & Weaknesses

Table 158. Pharmaoffer (NL) Basic Information, Manufacturing Base and Competitors

Table 159. Pharmaoffer (NL) Major Business

Table 160. Pharmaoffer (NL) Third-party Pharmaceutical B2B Platform Product and Services

Table 161. Pharmaoffer (NL) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 162. Pharmaoffer (NL) Recent Developments/Updates

Table 163. Pharmaoffer (NL) Competitive Strengths & Weaknesses

Table 164. AEP (DE) Basic Information, Manufacturing Base and Competitors

Table 165. AEP (DE) Major Business

Table 166. AEP (DE) Third-party Pharmaceutical B2B Platform Product and Services

Table 167. AEP (DE) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 168. AEP (DE) Recent Developments/Updates

Table 169. AEP (DE) Competitive Strengths & Weaknesses

Table 170. Validaide (NL) Basic Information, Manufacturing Base and Competitors

Table 171. Validaide (NL) Major Business

Table 172. Validaide (NL) Third-party Pharmaceutical B2B Platform Product and Services

Table 173. Validaide (NL) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 174. Validaide (NL) Recent Developments/Updates

Table 175. Validaide (NL) Competitive Strengths & Weaknesses

Table 176. Sanicare (DE) Basic Information, Manufacturing Base and Competitors

Table 177. Sanicare (DE) Major Business

Table 178. Sanicare (DE) Third-party Pharmaceutical B2B Platform Product and Services

Table 179. Sanicare (DE) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 180. Sanicare (DE) Recent Developments/Updates

Table 181. Sanicare (DE) Competitive Strengths & Weaknesses

Table 182. Zentiva (Zent2U) (CZ) Basic Information, Manufacturing Base and Competitors

Table 183. Zentiva (Zent2U) (CZ) Major Business

Table 184. Zentiva (Zent2U) (CZ) Third-party Pharmaceutical B2B Platform Product and Services

Table 185. Zentiva (Zent2U) (CZ) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 186. Zentiva (Zent2U) (CZ) Recent Developments/Updates

Table 187. Zentiva (Zent2U) (CZ) Competitive Strengths & Weaknesses

Table 188. DawaDose (SA) Basic Information, Manufacturing Base and Competitors

Table 189. DawaDose (SA) Major Business

Table 190. DawaDose (SA) Third-party Pharmaceutical B2B Platform Product and Services

Table 191. DawaDose (SA) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 192. DawaDose (SA) Recent Developments/Updates

Table 193. DawaDose (SA) Competitive Strengths & Weaknesses

Table 194. Dawaai (PK) Basic Information, Manufacturing Base and Competitors

Table 195. Dawaai (PK) Major Business

Table 196. Dawaai (PK) Third-party Pharmaceutical B2B Platform Product and Services

Table 197. Dawaai (PK) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 198. Dawaai (PK) Recent Developments/Updates

Table 199. Dawaai (PK) Competitive Strengths & Weaknesses

Table 200. PharmaHopers (IN) Basic Information, Manufacturing Base and Competitors

Table 201. PharmaHopers (IN) Major Business

Table 202. PharmaHopers (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 203. PharmaHopers (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 204. PharmaHopers (IN) Recent Developments/Updates

Table 205. PharmaHopers (IN) Competitive Strengths & Weaknesses

Table 206. MedPro (IN) Basic Information, Manufacturing Base and Competitors

Table 207. MedPro (IN) Major Business

Table 208. MedPro (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 209. MedPro (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 210. MedPro (IN) Recent Developments/Updates

Table 211. MedPro (IN) Competitive Strengths & Weaknesses

Table 212. PharmaSource D2R (IN) Basic Information, Manufacturing Base and Competitors

Table 213. PharmaSource D2R (IN) Major Business

Table 214. PharmaSource D2R (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 215. PharmaSource D2R (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 216. PharmaSource D2R (IN) Recent Developments/Updates

Table 217. PharmaSource D2R (IN) Competitive Strengths & Weaknesses

Table 218. Biddano (IN) Basic Information, Manufacturing Base and Competitors

Table 219. Biddano (IN) Major Business

Table 220. Biddano (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 221. Biddano (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 222. Biddano (IN) Recent Developments/Updates

Table 223. Biddano (IN) Competitive Strengths & Weaknesses

Table 224. Pharmint (IN) Basic Information, Manufacturing Base and Competitors

Table 225. Pharmint (IN) Major Business

Table 226. Pharmint (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 227. Pharmint (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 228. Pharmint (IN) Recent Developments/Updates

Table 229. Pharmint (IN) Competitive Strengths & Weaknesses

Table 230. HealthCRAD Wholesale (IN) Basic Information, Manufacturing Base and Competitors

Table 231. HealthCRAD Wholesale (IN) Major Business

Table 232. HealthCRAD Wholesale (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 233. HealthCRAD Wholesale (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 234. HealthCRAD Wholesale (IN) Recent Developments/Updates

Table 235. HealthCRAD Wholesale (IN) Competitive Strengths & Weaknesses

Table 236. TradeIndia (IN) Basic Information, Manufacturing Base and Competitors

Table 237. TradeIndia (IN) Major Business

Table 238. TradeIndia (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 239. TradeIndia (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 240. TradeIndia (IN) Recent Developments/Updates

Table 241. TradeIndia (IN) Competitive Strengths & Weaknesses

Table 242. ChemDmart (IN) Basic Information, Manufacturing Base and Competitors

Table 243. ChemDmart (IN) Major Business

Table 244. ChemDmart (IN) Third-party Pharmaceutical B2B Platform Product and Services

Table 245. ChemDmart (IN) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 246. ChemDmart (IN) Recent Developments/Updates

Table 247. ChemDmart (IN) Competitive Strengths & Weaknesses

Table 248. ConectNext (MX) Basic Information, Manufacturing Base and Competitors

Table 249. ConectNext (MX) Major Business

Table 250. ConectNext (MX) Third-party Pharmaceutical B2B Platform Product and Services

Table 251. ConectNext (MX) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 252. ConectNext (MX) Recent Developments/Updates

Table 253. ConectNext (MX) Competitive Strengths & Weaknesses

Table 254. Yaydoo (MX) Basic Information, Manufacturing Base and Competitors

Table 255. Yaydoo (MX) Major Business

Table 256. Yaydoo (MX) Third-party Pharmaceutical B2B Platform Product and Services

Table 257. Yaydoo (MX) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 258. Yaydoo (MX) Recent Developments/Updates

Table 259. Yaydoo (MX) Competitive Strengths & Weaknesses

Table 260. MercadoLibre (B2B Pharma) (AR) Basic Information, Manufacturing Base and Competitors

Table 261. MercadoLibre (B2B Pharma) (AR) Major Business

Table 262. MercadoLibre (B2B Pharma) (AR) Third-party Pharmaceutical B2B Platform Product and Services

Table 263. MercadoLibre (B2B Pharma) (AR) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 264. MercadoLibre (B2B Pharma) (AR) Recent Developments/Updates

Table 265. MercadoLibre (B2B Pharma) (AR) Competitive Strengths & Weaknesses

Table 266. Yeatrade (CO) Basic Information, Manufacturing Base and Competitors

Table 267. Yeatrade (CO) Major Business

Table 268. Yeatrade (CO) Third-party Pharmaceutical B2B Platform Product and Services

Table 269. Yeatrade (CO) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 270. Yeatrade (CO) Recent Developments/Updates

Table 271. Yeatrade (CO) Competitive Strengths & Weaknesses
Table 272. Axmed (CH) Basic Information, Manufacturing Base and Competitors
Table 273. Axmed (CH) Major Business
Table 274. Axmed (CH) Third-party Pharmaceutical B2B Platform Product and Services
Table 275. Axmed (CH) Third-party Pharmaceutical B2B Platform Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 276. Axmed (CH) Recent Developments/Updates
Table 277. Axmed (CH) Competitive Strengths & Weaknesses
Table 278. Global Key Players of Third-party Pharmaceutical B2B Platform Upstream (Raw Materials)
Table 279. Global Third-party Pharmaceutical B2B Platform Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Third-party Pharmaceutical B2B Platform Picture

Figure 2. World Third-party Pharmaceutical B2B Platform Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Third-party Pharmaceutical B2B Platform Total Revenue (2021-2032) & (USD Million)

Figure 4. World Third-party Pharmaceutical B2B Platform Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World Third-party Pharmaceutical B2B Platform Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company Third-party Pharmaceutical B2B Platform Revenue (2021-2032) & (USD Million)

Figure 13. Third-party Pharmaceutical B2B Platform Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 16. World Third-party Pharmaceutical B2B Platform Consumption Value Market Share by Region (2021-2032)

Figure 17. United States Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 18. China Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 23. India Third-party Pharmaceutical B2B Platform Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Third-party Pharmaceutical B2B Platform by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Third-party Pharmaceutical B2B Platform Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Third-party Pharmaceutical B2B Platform Markets in 2025

Figure 27. United States VS China: Third-party Pharmaceutical B2B Platform Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Third-party Pharmaceutical B2B Platform Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Third-party Pharmaceutical B2B Platform Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Type in 2025

Figure 31. Pure matching platform

Figure 32. Hybrid platform (matching + self-operated)

Figure 33. Supply chain collaboration platform

Figure 34. API-first platform

Figure 35. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Type (2021-2032)

Figure 36. World Third-party Pharmaceutical B2B Platform Market Size by Product Category, (USD Million), 2021 & 2025 & 2032

Figure 37. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Product Category in 2025

Figure 38. Full-category pharmaceutical platform (approx. 55-60%)

Figure 39. API & bulk drug platform (approx. 15-20%)

Figure 40. Medical device & equipment platform (approx. 10-15%)

Figure 41. Chinese traditional medicine platform (approx. 8-12%)

Figure 42. Healthcare & wellness platform (approx. 5-8%)

Figure 43. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Product Category (2021-2032)

Figure 44. World Third-party Pharmaceutical B2B Platform Market Size by Module, (USD Million), 2021 & 2025 & 2032

Figure 45. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Module in 2025

Figure 46. Online ordering & inventory management

Figure 47. Regulatory compliance & licensing

Figure 48. Cold chain validation

Figure 49. Sample & promotional product management

Figure 50. Price comparison & dynamic pricing

Figure 51. Others

Figure 52. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Module (2021-2032)

Figure 53. World Third-party Pharmaceutical B2B Platform Market Size by Core Revenue, (USD Million), 2021 & 2025 & 2032

Figure 54. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Core Revenue in 2025

Figure 55. Commission-based

Figure 56. Subscription/membership

Figure 57. Service fee (SaaS/data)

Figure 58. Hybrid

Figure 59. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Core Revenue (2021-2032)

Figure 60. World Third-party Pharmaceutical B2B Platform Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 61. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Application in 2025

Figure 62. Retail pharmacies

Figure 63. Hospitals & clinics

Figure 64. Pharmaceutical manufacturers

Figure 65. Wholesalers & distributors

Figure 66. Primary care & community clinics

Figure 67. Others

Figure 68. World Third-party Pharmaceutical B2B Platform Market Size Market Share by Application (2021-2032)

Figure 69. Third-party Pharmaceutical B2B Platform Industrial Chain

Figure 70. Methodology

Figure 71. Research Process and Data Source

I would like to order

Product name: Global Third-party Pharmaceutical B2B Platform Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G574EFBA7FE9EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G574EFBA7FE9EN.html>